Review Article
Managing Lymphoma with Non-FDG Radiotracers: Current Clinical and Preclinical Applications
Table 2
The current available radiopharmaceuticals for radioimmunotherapy of lymphoma.
| | -Zevalin |
131I-Bexxar |
131I-Rituximab |
| Radioisotope | ( = 2.67 days) |
131I ( = 8.01 days) |
131I ( = 8.01 days) | Anti-CD20 antibody | Ibritumomab tiuxetan | Tositumomab | Rituximab | Antibody type | Monoclonal murine | Monoclonal murine | Monoclonal chimeric | Predose injection | Unlabeled rituximab | Unlabeled tositumomab | Unlabeled rituximab | Pretherapy imaging | Yes (for biodistribution) | Yes (for dosimetry) | Yes (for dosimetry) | Pretherapy dose | 111In-Zevalin (5 mCi) |
131I-Bexxar (5 mCi) |
131I-Rituximab (5 mCi) | Treatment dose | 0.4 mCi/kg (up to 32 mCi) | 75 cGy (whole body) | 75 cGy (whole body) |
|
|